Management of aerobic vaginitis.
Aerobic vaginitis is a new nonclassifiable pathology that is neither specific vaginitis nor bacterial vaginosis. The diversity of this microbiological peculiarity could also explain several therapeutic failures when patients were treated for infections identified as bacterial vaginosis. The diagnosis 'aerobic vaginitis' is essentially based on microscopic examinations using a phase-contrast microscope (at ×400 magnification). The therapeutic choice for 'aerobic vaginitis' should take into consideration an antibiotic characterized by an intrinsic activity against the majority of bacteria of fecal origin, bactericidal effect and poor/absent interference with the vaginal microbiota. Regarding the therapy for aerobic vaginitis when antimicrobial agents are prescribed, not only the antimicrobial spectrum but also the presumed ecological disturbance on the anaerobic and aerobic vaginal and rectal microbiota should be taken into a consideration. Because of their very low impact on the vaginal microbiota, kanamycin or quinolones are to be considered a good choice for therapy.
Department of Microbiological and Gynecological Sciences, University of Catania, Catania, Italy. tempera @ unict.it
Gianna
G
Tempera
Pio Maria
PM
Furneri
D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D001420:Bacteria, Aerobic / Q000166:cytology / Q000302:isolation & purification; D004755:Enterobacteriaceae / Q000187:drug effects; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D007778:Lactobacillus / Q000187:drug effects; D015363:Quinolones / Q000627:therapeutic use; D014621:Vagina / Q000382:microbiology; D016585:Vaginosis, Bacterial / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D015363:Quinolones; D007612:Kanamycin